Conquering Diseases

Study Of The Safety And Efficacy Of Investigational Monoclonal Antibodies For Mild To Moderate Covid-19 (Blaze-1)

Description

Seeking individuals over 12 years of age with mild to moderate COVID-19 illness, but have not yet been hospitalized for a study of investigational monoclonal antibodies against COVID-19.

Overview

The purpose of this study is to measure how well monoclonal antibodies given alone or in combination work against the virus that causes COVID-19. Investigational antibodies (LY3819253 alone or in combination with LY3832479) or placebo (looks like the drug but does not contain active medicine) will be given to participants with early symptoms of COVID-19, via an injection into a vein.

What we're hoping for

Evaluate how safe investigational monoclonal antibodies are and how well they will work to help reduce symptoms and the amount of virus in people with mild to moderate COVID-19.

Additional Information

ClinicalTrials.gov Identifier: NCT04427501

 Principal Investigator

Robert  Finberg, MD

University of Massachusetts Medical School

 Study Contact

Shestruma  Parajuli

shestruma.parajuli@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989